Schering Plough Corp
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
Expressing industry’s frustration at FDA’s capriciousness and intransigence, Fred Hassan, then CEO of drug company Schering-Plough, said of the regulatory climate: “What will it take to get new drugs approved? The point is, we don’t know.” Kenneth... Full Article at Hoover Institution
-
Xiangxue Pharmaceutical to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
Biospace
I am delighted to have the opportunity to work closely with their clinical development team." About Kinex Pharmaceuticals, LLC Kinex Pharmaceuticals, headquartered in Buffalo, New York , USA, is using its proprietary technologies Mimetica and Opal to... Full Article at Biospace
-
FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1
Business Wire
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved a labeling update for ISENTRESS® (raltegravir) Film-coated Tablets to... Full Article at Business Wire
-
Experts Offer Guidance on Use of DAAs for Difficult-To-Treat Hep C Patients
Infectious Disease Special Edition
San Francisco—For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals (DAAs) perform in the patients who are most in need of a... Full Article at Infectious Disease Special Edition
-
I would consider Roche in the next December-February time frame, as the dividend date draws nearer once again. I like the fact that management is aggressively seeking opportunities to complement the firms' strengths. Merck: Morningstar gives kudos to... Full Article at Seeking Alpha
-
-
SACV11-00146 in the Central District of California); and Schering-Plough (Valadez v. Schering-Plough, Case No. 10-CV-2595 in the Southern District of California). For more information about the Medimmune Biologics class action lawsuit, call (866)... Full Article at PRWeb
-
Merck is in the final stages of the integration of the Merck and Schering-Plough businesses in a worldwide restructuring program. It expects that the merger will be substantially completed by 2015. The cost of the merger has averaged about $1.6 billion... Full Article at Seeking Alpha
-
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the... Full Article at PR Newswire
About this topic
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Search Independent.ie topics
Related topics
Related videos
Related Conversations
Newsmap
See the geographical connection between Schering Plough Corp and different parts of the world. Mouse over the map pins to explore connections.
There are no results for this module.
Sponsored Features
Highlights
Independentwoman.ie
Independent Woman
A fresh, fun site featuring celeb gossip, fashion, beauty, love & sex, and health & fitness.
- Independent Channels:
-
RSSLearn more...
-
MobileLearn more...
-
FacebookLearn more...
